Hester Biosciences Limited — Investor Meet, 02-02-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Hester Biosciences reported strong Q3 FY26 standalone revenue growth of 12% and a 140% jump in PAT YoY, driven by a favorable product mix. Poultry Healthcare surged 32% in Q3. The H9N2 Avian Influenza vaccine received licenses, strengthening the poultry portfolio for domestic and export. Animal Healthcare declined 38% in Q3 due to delayed government immunization programs, expected to resume from February 2026.

Management anticipates current profitability to be sustainable, targeting year-on-year margin improvement. A new fill/finish facility has doubled drug product capacity, supporting existing and future export growth. Strategic focus remains on reducing tender reliance, expanding commercial/export markets, and innovation for a stronger, balanced performance.